Lv4
510 积分 2021-10-19 加入
Population Pharmacokinetics of siRNA JNJ ‐73763989 in Healthy Participants and Patients With Chronic Hepatitis B
16小时前
待确认
ADME considerations for siRNA-based therapeutics
20天前
已完结
Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies
1个月前
已完结
First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection
2个月前
已完结
OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
2个月前
已完结
Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C
2个月前
已完结
LBP-008 Safety, tolerability, and remarkable hepatitis B surface antigen reduction in chronic hepatitis B patients treated with BW-20507
2个月前
已关闭
First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection
2个月前
已完结
Control of Hepatitis B Virus with Imdusiran, a Small Interfering RNA Therapeutic
2个月前
已完结
Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ‐73763989 in Healthy Chinese Adult Participants
3个月前
已完结
皖公网安备34019202002308
